Cancer/testis antigen 1 (123-137)

Cancer/testis antigen 1 (123-137) is a synthetic peptide fragment derived from the immunodominant region of the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. This peptide sequence encompasses amino acids 123 to 137, representing a region frequently recognized by both humoral and cellular immune responses in various malignancies. As a member of the cancer/testis antigen family, it is characterized by restricted expression in normal adult tissues, primarily the testis, but is aberrantly expressed in a broad spectrum of tumors. The unique expression profile and immunogenic properties of this peptide make it a valuable tool for research into tumor immunology, antigen processing, and immune recognition mechanisms.

Epitope mapping: The 123-137 fragment serves as a defined epitope for detailed mapping of T cell and antibody responses against NY-ESO-1. Researchers utilize this peptide to identify and characterize the specific immune cell populations that recognize the antigen, enabling the study of antigen-specific T cell receptor usage, epitope dominance, and cross-reactivity with related sequences. Such mapping efforts are crucial for understanding the immune landscape in cancer patients and for guiding the design of targeted immunotherapeutic strategies.

Immunogenicity studies: The peptide is widely used in ex vivo and in vitro assays to assess the immunogenic potential of NY-ESO-1-derived sequences. By stimulating peripheral blood mononuclear cells (PBMCs) or isolated T lymphocytes from cancer patients or healthy donors with this fragment, investigators can evaluate cytokine production, proliferation, and cytotoxic activity. These studies provide valuable insights into the mechanisms of tumor antigen recognition, the breadth of immune responses across patient populations, and the identification of potential biomarkers for immune monitoring.

Peptide-based vaccine research: The 123-137 region of NY-ESO-1 is of particular interest for the development of peptide-based cancer vaccines. Researchers employ this peptide in preclinical models to evaluate its capacity to elicit robust and specific cellular immune responses. Such investigations inform the rational selection and optimization of antigenic peptides for inclusion in experimental vaccine formulations, with the goal of enhancing anti-tumor immunity through precise immune targeting.

MHC binding assays: The defined sequence of this peptide allows for systematic analysis of its binding affinity and stability with various major histocompatibility complex (MHC) class I and II molecules. These assays are essential for elucidating the molecular determinants of antigen presentation, predicting patient-specific immune responses, and refining computational models of peptide-MHC interactions. The results contribute to a deeper understanding of the antigen processing and presentation pathways relevant to tumor immunology.

Assay development and quality control: The Cancer/testis antigen 1 (123-137) peptide is frequently employed as a positive control or standard in the development and validation of immunoassays, including ELISPOT, ELISA, and intracellular cytokine staining protocols. Its well-characterized immunogenicity and sequence specificity make it an ideal reference for optimizing assay sensitivity, reproducibility, and specificity. Incorporating this peptide into assay workflows enhances the reliability of immune monitoring in both basic research and translational studies focused on cancer immunology.

1. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

2. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

3. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma